靶向肠道微生物组治疗原发性硬化性胆管炎:概念框架
本文提出原发性硬化性胆管炎(PSC)的病理生理可概念化为肠道菌群失调、胆汁酸代谢改变和免疫介导的胆管损伤三联征。肠道菌群与胆汁酸双向互动,其改变可能是PSC的病因而非结果。目前肝移植是唯一确立的挽救生命的治疗,抗菌治疗或粪菌移植是新兴选择,其有益效应可能通过改变肠道菌群并改善胆汁酸代谢介导。
要点
- PSC病理生理可概念化为肠道菌群失调、胆汁酸代谢改变和免疫介导胆管损伤三联征。
- 肠道菌群与胆汁酸双向互动,其改变可能是PSC的病因而非结果。
- 肝移植是唯一确立的挽救生命治疗,抗菌治疗或粪菌移植为新兴选择。
核心结论
- PSC的病理生理可概念化为肠道菌群失调、胆汁酸代谢改变和免疫介导的胆管损伤三联征。
- 肠道菌群和胆汁酸的改变可能是PSC的病因而非结果。
- 肝移植是目前唯一确立的挽救生命的治疗,抗菌治疗或粪菌移植是新兴治疗选择。
研究设计与样本
- 本文为概念性框架综述,未报告系统检索范围或样本量。
主要发现
- PSC是一种罕见的免疫介导的慢性胆汁淤积性肝病,与以全结肠炎且右侧为主为特征的炎症性肠病相关。
- 胆汁酸塑造肠道微生物组,而肠道微生物有潜力改变胆汁酸。
- PSC在家族中聚集,提示其发生于遗传易感个体。
- 免疫激活似乎是疾病过程的核心,但免疫抑制不改善临床结局或改变PSC自然病程。
- 抗菌治疗或粪菌移植的有益效应可能通过改变肠道微生物组并对胆汁酸代谢产生有利影响而介导。
临床怎么用
- 目前肝移植是唯一确立的挽救生命的PSC治疗。
- 抗菌治疗或粪菌移植是PSC的新兴治疗选择,其效应可能通过改变肠道微生物组和胆汁酸代谢介导。
- 未来个性化方法将更好地靶向微生物组、免疫功能和胆汁酸代谢之间的相互依赖。
局限性
- 本文为概念性框架综述,未报告系统检索范围或原始研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary sclerosing cholangitis (PSC) is a rare, immune-mediated, chronic cholestatic liver disease associated with a unique phenotype of inflammatory bowel disease that frequently manifests as pancolitis with right-sided predominance. Available data suggest a bidirectional interplay of the gut-liver axis with critical roles for the gastrointestinal microbiome and circulating bile acids (BAs) in the pathophysiology of PSC. BAs shape the gut microbiome, whereas gut microbes have the potential to alter BAs, and there are emerging data that alterations of BAs and the microbiome are not simply a consequence but the cause of PSC. Clustering of PSC in families may suggest that PSC occurs in genetically susceptible individuals. After exposure to an environmental trigger (e.g., microbial byproducts or BAs), an aberrant or exaggerated cholangiocyte-induced immune cascade occurs, ultimately leading to bile duct damage and progressive fibrosis. The pathophysiology can be conceptualized as a triad of (1) gut dysbiosis, (2) altered BA metabolism, and (3) immune-mediated biliary injury. Immune activation seems to be central to the disease process, but immunosuppression does not improve clinical outcomes or alter the natural history of PSC. Currently, orthoptic liver transplantation is the only established life-saving treatment, whereas antimicrobial therapy or fecal transplantation is an emerging therapeutic option for PSC. The beneficial effects of these microbiome-based therapies are likely mediated by a shift of the gut microbiome with favorable effects on BA metabolism. In the future, personalized approaches will allow to better target the interdependence between microbiome, immune function, and BA metabolism and potentially cure patients with PSC.
引用
- Shah A, Macdonald GA, Morrison M, et al. Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework. Am J Gastroenterol. 2020. PMID: 32250997. doi:10.14309/ajg.0000000000000604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。